EpiPen competitor earns FDA approval: 5 things to know

The Food and Drug Administration June 15 approved Symjepi, an epinephrine injection developed by Adamis Pharmaceuticals Corp.

Here are five things to know.

  1. Symjepi is a single-dose prefilled syringe of epinephrine intended to treat emergency allergic reactions, including anaphylaxis.

  1. The injection will directly compete with Mylan's EpiPen, which holds a majority of the epinihprine injection market.

  1. Adamis has not disclosed an official price for Symjepi. The drugmaker hopes to sell a two-pack of Symjepi for cheaper than Mylan's generic EpiPens, which cost $300 for a pack of two, reports CBS News.

  1. The drugmaker plans to launch the product in the second half of 2017.

  1. Adamis will also submit a new drug application to the FDA for a lower-dose version of Symjepi, which will compete with Mylan's EpiPen Jr.

More articles on supply chain:

Nevada governor signs drug price transparency legislation: 5 things to know
Hospira recalls several injectables over sterility concerns
Trump administration readies executive order addressing drug prices

© Copyright ASC COMMUNICATIONS 2020. Interested in LINKING to or REPRINTING this content? View our policies by clicking here.


Featured Content

Featured Webinars

Featured Whitepapers